Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
The Future Of Aging – A Conversation With Dr. Eric Leire
Nov 6, 2023 | The Futurist Society
Many of us strive towards living long lives; but just as health risks grow as we age,
hTtps://www.thefuturistsociety.net/the-future-of-aging-a-conversation-with-dr-eric-leire
Plenty of dosh flowing into the longevity space, fingers crossed Genflow's turn soon. Gla holders , let's hope Eric has a flow of good news to report into Christmas and the New Year.:-)
Biolexis lands $10m to advance metabolic drug program with longevity potential
2 HOURS AGO
hTtps://longevity.technology/news/biolexis-lands-10m-to-advance-metabolic-drug-program-with-longevity-potential/amp/
GenFlow Biosciences
1,340 followers
15m
ArrivoBio has secured $45 million in Series B financing to progress its novel drug candidates, including SP-624 for major depressive disorder (MDD). SP-624, a groundbreaking treatment, activates the SIRT6 enzyme, offering a new approach to managing MDD. At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) we are pioneering research on SIRT6 to unlock its potential to extend healthspan and fight aging. Our dedicated efforts in this domain underscore the importance of genetic research in tackling major health issues like aging and mental health. Read about it here: https://loom.ly/GBsJLeY #SIRT6 #healthspan #longevity #mentalhealth
ArrivoBio Raises $45M in Series B Financing to Advance Pipeline | BioSpacebiospace.com
Good Morning Porter, not me but i've had a couple of top ups this week in anticipation of imminent news from Eric, and very much looking forward to a stellar 2024 for Genflow. Gl ;-)
Get UP there!!! Gla holders...news from Eric on grants/funding expected soon along with 4 final invivo studies from Genflows High profile academic collaborations....news of a Major investor and or JV partner at anytime. :-)
28/9/23
The Company continues to maintain a secure financial position and has sufficient cash reserves until March 2025. This is inclusive of grant funding which has been approved at the time of reporting and is due to be received in the coming months. The Company continues to seek further non-dilutive research grants which management will use to expedite specific phases of planned research and development.
......
The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.
These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.
But even the companies regarded as the cream-of-crop are at a disadvantage…
They tend to focus on a single hallmark of aging. To quote Eric Leire, the company’s chief executive, “You’ve only solved one-ninth of the problem with this approach.”
Genflow Biosciences takes a holistic approach by targeting 4 of the 9 hallmarks directly, in addition to 2 indirectly. They are able to do this by focusing on the SIRT6 gene. This gene’s overexpression has proven to extend the lives of healthy mice, winning it the title of the “master regulator of aging”.
This novel research has allowed the company to capture alluring patents, which brings us back to Altos Labs…
If anyone wants this IP they would have to purchase the company at a significant premium to the current share price or enter a licensing agreement.
Altos Labs opened only last year, in January of 2022. We know that Altos Labs has the ambition and the means to become the leader in longevity tech, and Genflow Biosciences likely holds the keys to that ambition.
It stands to reason that Genflow Biosciences could become an attractive acquisition target for a mega-tech startup such as Altos Labs.
Markets are extremely sensitive to takeovers, and the mere rumour of a potential acquisition could result in a drastic increase in Genflow's significantly undervalued share price
News like this could pop at any second. Launching Genflow Biosciences into the spotlight at any time this year.
This is a highly competitive industry and players with deep pockets see Genflow Biosciences’ IP as their ticket to the top of the market. If it’s not Altos Labs, then surely there will be another.
That is why I am recommending readers take a close look at it right now.
The company is currently eyeing a listing in other markets and a US listing may be on the horizon.
If I were to bet on the next big biotech stock story, Genflow BioSciences would be it.
A company I believe is set to explode and has the potential to rise significantly in the near term.
What justifies such a bold prediction?
This company may hold the keys to the cure for aging...
The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.
Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*
The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.
But before I go any further, let me ask you something…
Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?
According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.
With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.
But backing from big names isn’t the only ace up the sleeve of Altos Labs…
The company has built an executive dream team of industry experts and scientific luminaries.
Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.
What is reprogramming and why is it important you might ask?
Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.
Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?
Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.
With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”
But what does all of this have to do with Genflow Biosciences potentially significant rise in value?
I’m going to tell you, but first, let’s get some background.
Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).
Okay, but why should we expect such sudden exponential growth.
The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...
To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.
But even the companies regarded as the cream-of-crop are at a disadvantage…
Joe's call was slightly early in proceedings, but maybe this time he will be on the money along with Genflow and those invested at this rockbottom bargain low, this coming year 2024. Gla ;-)
Here's why this UK BioTech stock could potentially be set to rise imminently
Saturday 4th February 2023
Author: Joe Neighbour (MSTA)
Joe started his career in financial services with HSBC at 18 years old before moving into broking arena at several small to medium-size firms. It was here that Joe gained vast experience in dealing with high net worth individuals and providing wealth solutions.
He began to develop a passion for technical analysis and this desire to learn more about markets sent him down a path of trading. Joe became involved in trading markets just before the 2008 financial crisis and had to quickly adapt to some very challenging conditions.
Joe is a Member of the Society of Technical Analysis (MSTA) and Chartered Fellow (CISI). He has 15+ years’ experience in financial markets across a variety of roles including broking, portfolio managing, and analysis.
Updates
View organization page for GenFlow Biosciences
GenFlow Biosciences
1,339 followers
22m
The XPrize Foundation, known for fueling innovative research, has announced a $101 million prize for advancements in anti-aging therapies. The aim is to develop treatments that can significantly reverse aging effects in individuals aged 65-80, focusing on improving muscle, cognition, and immune function. This initiative, the largest in XPrize history, is a testament to the growing importance and potential of longevity research.
At GenFlow Biosciences (LSE: GENF)(OTCQB: GENFF) we believe that aging deserves as much attention as any other global health issue. Our approach, which employs advanced gene delivery techniques, is in the vanguard of addressing the challenges and opportunities of an aging population.
Read more here: hTtps://loom.ly/5zPTJM4
#XPrize #longevity #healthspan #genetherapy
The live feed for the summit has been down all day and so no idea what's been happening, but Eric Verdin CEO of the Buck Institute who sits on Genflow’s Scientific Advisory Board has received $21m in funding. Gl :-)
Updated: 30 November ,2023: 01:32 PM GST
Saudi Arabia’s billion-dollar-a-year anti-aging initiative, the Hevolution Foundation, has announced scientific research grants worth $40 million to fuel transformative breakthroughs in aging science on the closing day of the inaugural Global Healthspan Summit.
Major funding announcements on Thursday included initial pledges $40 million which include $21 million for a novel multi-year partnership with the Buck Institute for Research on Aging to accelerate discoveries toward therapeutic interventions specifically targeting aging.
Cheers Northeast, exciting time to be invested, and this is in addition to Hevolution's planned investments and strategic partnerships which are expected to be announced tomorrow. Gl :-)
XPRIZE on aging will award up to $101 million for therapies that restore vigor to the elderly
Backed by Lulemon’s creator and a Saudi foundation, competition aims to find treatments to extend “health span”
29 NOV 2023
The XPRIZE Foundation today announced $101 million in prizes for researchers who can restore the function of an elderly person’s muscle, cognition, and immune system to a more youthful state.
The competition, backed by Saudi money and the success of a women’s athletic clothing line, seeks drugs, other therapies, and lifestyle strategies that target the biology of human aging to extend a person’s “health span,” or the period of life free of disease or disability. Such breakthroughs could also help prevent chronic diseases closely linked to aging that threaten to overwhelm the health care system. “This is the decade where we’ll see a health span revolution,” says Peter Diamandis, XPRIZE’s founder and executive chair.
htTps://www.xprize.org/prizes/healthspan
Hevolution Global Healthspan Summit...live stream
htTps://m.youtube.com/watch?v=0KT9v_NFfak
Ps Dr Khan was CEO at Life Biosciences, which was founded by the one and only David Sinclair, and so will obviously be very well aware of the potential potency of Sirt6 in longevity, healthspan and multiple disease targets. Gl ;-)
hTtps://www.lifebiosciences.com/dr-mehmood-khan-named-ceo-of-life-biosciences/
Every chance Genflow could be in the frame for significant investment from Hevolution, which would see the sp multi-bag on confirmation. They plan to invest $1 Billion a year to transform R & D into the Longevity space, Major announcements on science, capital investments and strategic partnerships will be made this coming week at Hevolution's Global Healthspan Summit 29-30 November, 2023 Gla :-)
hTtps://youtu.be/_bZCJKV8lRw?si=0QZgDT1sb1ebl19k
Another brilliant and exciting interview with Dr Khan , CEO of Hevolution with Longevity Technology who are invested in Genflow.
Dr Khan confirms there will be major announcements at next week's summit on science, capital and investments, with research institutions and scientists around the world with focus on strategic partnerships and research grants and funding with Academic research institutions and investments into Biotech companies involved with taking the science from Academi research institutions and progressing the R&D towards market....which is exactly what Genflow are doing!!! Gla holders...Excitement building. :-)
Our vision statement is clear: Expand healthy lifespan for the benefit of all’
hTtps://longevity.technology/news/our-vision-statement-is-clear-expand-healthy-lifespan-for-the-benefit-of-all/amp/